Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An announcement from Prescient Therapeutics Limited ( (AU:PTX) ) is now available.
Prescient Therapeutics has successfully received FDA clearance for its IND application, enabling the immediate initiation of a Phase 2 clinical trial for PTX-100, targeting relapsed and refractory cutaneous T-cell lymphomas. Additionally, Prescient has made significant strides in its cell therapy platforms, with increased interest in collaborations and ongoing development of its CellPryme and OmniCAR technologies. The company remains financially stable with an $8.4 million cash balance and a recent $3.7 million R&D tax rebate, ensuring continued investment in research and development. The appointment of James McDonnell as CEO, with his extensive experience in the pharmaceutical industry, is expected to further strengthen the company’s leadership and strategic initiatives.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited is a clinical stage oncology company that specializes in developing personalized therapies for cancer. It is focused on advancing its innovative treatments through rigorous clinical trials, particularly targeting relapsed and refractory cancers.
YTD Price Performance: 8.00%
Average Trading Volume: 712,183
Technical Sentiment Consensus Rating: Hold
Current Market Cap: A$46.71M
For detailed information about PTX stock, go to TipRanks’ Stock Analysis page.
